PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

New Anaerobic Activity Index Quantifies Anti-Anaerobic Antibiotic Exposure

Anaerobic Activity IndexAAImeropenemertapenemtigecyclinemetronidazolepiperacillin-tazobactamcefepimeanti-anaerobic antibioticsantimicrobial stewardshipspectrum scoreDASCmASIburn patientssepsisgut microbiomeobservational cohortmethodological study Infectious Disease / Antimicrobials

Background Information

A new index ranks antibiotics by anaerobic activity exposure.

Antibiotics with anaerobic activity can lead to unfavorable outcomes in burn patients, necessitating a reliable way to quantify exposure. The Anaerobic Activity Index (AAI) ranks antibiotics based on anaerobic activity, with meropenem having the highest score. Higher AAI quartiles were linked to worse outcomes (OR: 2.90; 95% CI: 1.65-5.08). The AAI provides a tool to evaluate antibiotic effects on anaerobic bacteria, though it requires updates with new data and excludes some antibiotics due to insufficient data. The Anaerobic Activity Index helps quantify exposure to anaerobic-active antibiotics, potentially influencing patient outcomes.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Mackow NA, Komarow L, Napravnik S, Andermann TM, Bartelt L, DiBiase LM, Williams B, Williams FN, Young VB, Aronoff DM, Weber DJ, Chanderraj R, van Duin D

Citation: Mackow NA, Komarow L, Napravnik S, et al. Development and Application of an Anaerobic Activity Index. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2026. doi:10.1093/cid/ciag470

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.